Spleen tyrosine kinase inhibitors for rheumatoid arthritis: Where are we now?

Drugs

Volumn 74, Issue 4, 2014, Pages 415-422

  Scott, Ian C ^a,b   Scott, David L ^c  

^a GUY S HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FOSTAMATINIB; JANUS KINASE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE SYK INHIBITOR; ANTIRHEUMATIC AGENT; OXAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE;

DIARRHEA; DISABILITY; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; HYPERTENSION; MACROPHAGE; MULTICENTER STUDY (TOPIC); NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW (TOPIC); ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL (TOPIC); ENZYMOLOGY; SPLEEN; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; HUMANS; OXAZINES; PROTEIN-TYROSINE KINASES; PYRIDINES; SPLEEN; TREATMENT OUTCOME;

EID: 84897112247     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0193-9     Document Type: Review

References (31)

1. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Sao Paulo Med J. 2010;128:309-10.
2. Stanczyk J, Ospelt C, Gay S. Is there a future for small molecule drugs in the treatment of rheumatic diseases? Curr Opin Rheumatol. 2008;20:257-62. (Pubitemid 351483313)
3. Kelly V, Genovese M. Novel small molecule therapeutics in rheumatoid arthritis. Rheumatology. 2013;52:1155-62.
4. Sweeney SE, Firestein GS. Signal transduction in rheumatoid arthritis. Curr Opin Rheumatol. 2004;16:231-7. (Pubitemid 38530491)
5. Arthur JSC, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol. 2013;13:679-92.
6. Cohen SB, Cheng T-T, Chindalore V, Damjanov N, Burgos-Vargas R, Delora P, et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum. 2009;60:335-44.
7. Hammaker D, Firestein GS. "Go upstream, young man": lessons learned from the p38 saga. Ann Rheum Dis. 2010;69(Suppl 1):i77-82.
8. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228:273-87.
9. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381:451-60.
10. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495-507.
11. Sada K, Takano T, Yanagi S, Yamamura H. Structure and function of Syk protein-tyrosine kinase. J Biochem. 2001;130:177-86. (Pubitemid 32785863)
12. Pine PR, Chang B, Schoettler N, Banquerigo ML, Wang S, Lau A, et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol. 2007;124:244-57. (Pubitemid 47247604)
13. Genovese MC, Kavanaugh A, Weinblatt ME, Peterfy C, DiCarlo J, White ML, et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum. 2011;63:337-45.
14. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 2008;58:3309-18.
15. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med. 2010;363:1303-12.
16. Taylor PC, Genovese MC, Greenwood M, Ho M, Nasonov E, Oemar B, et al. Oskira-4: a phase IIB randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. Ann Rheum Dis. 2013;72:66.
17. Dawes P, Dimic A, Genovese MC, van der Heijde D, Jenkins M, O'Brien C, et al. Oskira-2: a phase III, multicenter, randomized, double-blind, placebo-controlled parallel-group study of 2 dosing regimens of fostamatinib in rheumatoid arthritis patients with an inadequate response to disease-modifying antirheumatic drugs [abstract]. Arthritis Rheum. 2013;65:455.
18. Genovese M, van der Heijde D, Keystone E, Spindler A, Benhamou C, Kavanaugh A, et al. Oskira-3: a phase III, multicenter, randomized, double-blind, placebo-controlled parallel-group study of 2 dosing regimens of fostamatinib in rheumatoid arthritis patients with an inadequate response to a tumor necrosis factor-a antagonist [abstract]. Arthritis Rheum. 2013;65:456.
19. Weinblatt M, Genovese MC, Ho M, Hollis S, Rosiak-Jedrychowicz K, Kavanaugh A, et al. Oskira-1: a phase III, multicenter, randomized, double-blind, placebo-controlled parallelgroup study of 2 dosing regimens of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate [abstract]. Arthritis Rheum. 2013;65:1793.
20. Wolfe F, Michaud K, Strand V. Expanding the definition of clinical differences: from minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis. J Rheumatol. 2005;32:583-9. (Pubitemid 40524688)
21. Weinblatt ME, Kavanaugh A, Genovese MC, Jones DA, Musser TK, Grossbard EB, et al. Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2013;40:369-78.
22. Kavanaugh A, Weinblatt ME, Genovese MC, Musser TK, Grossbard EB, Magilavy DB, et al. Longer-term safety of fostamatinib (R788) in patients with rheumatoid arthritis analysis of clinical trial data from up to 2 years of exposure [abstract]. Arthritis Rheum. 2011;63:2594.
23. Kazerounian S, Duquette M, Reyes MA, Lawler JT, Song K, Perruzzi C, et al. Priming of the vascular endothelial growth factor signaling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase. Blood. 2011;117:4658-66.
24. Nijjar JS, Tindell A, McInnes IB, Siebert S. Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis. Rheumatology. 2013;52:1556-62.
25. Okamoto H, Kobayashi A. Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med. 2011;364:83-4 (author reply 4).
26. Salgado E, Maneiro JR, Carmona L, Gomez-Reino JJ. Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis. 2013 (Epub ahead of print).
27. He Y, Wong AY, Chan EW, Lau WC, Man KK, Chui CS, et al. Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2013;14:298.
28. Gaujoux-Viala C, Nam J, Ramiro S, Landewé R, Buch MH, Smolen JS, et al. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014 (Epub ahead of print).
29. Scott DL. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin Pharmacol Ther. 2012;91:30-43.
30. Pincus T, Yazici Y, Sokka T. Quantitative measures of rheumatic diseases for clinical research versus standard clinical care: differences, advantages and limitations. Best Pract Res Clin Rheumatol. 2007;21:601-28. (Pubitemid 47189089)
31. Rahman MU, Buchanan J, Doyle MK, Hsia EC, Gathany T, Parasuraman S, et al. Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. Ann Rheum Dis. 2011;70:1631-40.